Skip to main content
Canna~Fangled Abstracts

Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial

By September 9, 2021September 28th, 2021No Comments
. 2021 Sep 9;12:729800.

doi: 10.3389/fpsyt.2021.729800. eCollection 2021.

Erin L Martin 1, Justin C Strickland 2, Nicolas J Schlienz 3 4, Joel Munson 4, Heather Jackson 4, Marcel O Bonn-Miller 5, Ryan Vandrey 2
Affiliations 

Abstract

Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on symptoms of anxiety and depression. The aim of the present observational study was to assess general health in medicinal cannabis users and non-using controls with anxiety and/or depression.

Methods: Participants (368 Cannabis Users; 170 Controls) completed an online survey assessing anxiety and depressive symptoms, cannabis product use, sleep, quality of life, and comorbid chronic pain. Participants that completed this baseline survey were then invited to complete additional follow-up surveys at 3-month intervals. Baseline differences between Cannabis Users and Controls were assessed using independent-samples t-tests and generalized linear mixed effects models were used to assess the impact of initiating cannabis product use, sustained use, or discontinuation of use on anxiety and depressive symptoms at follow-up.

Results: Medicinal cannabis use was associated with lower self-reported depression, but not anxiety, at baseline. Medicinal cannabis users also reported superior sleep, quality of life, and less pain on average. Initiation of medicinal cannabis during the follow-up period was associated with significantly decreased anxiety and depressive symptoms, an effect that was not observed in Controls that never initiated cannabis use.

Conclusions: Medicinal cannabis use may reduce anxiety and depressive symptoms in clinically anxious and depressed populations. Future placebo-controlled studies are necessary to replicate these findings and to determine the route of administration, dose, and product formulation characteristics to optimize clinical outcomes.

 

Keywords: CBD-cannabidiol, THC-tetrahydrocannabinol, anxiety, cannabis, depression

Conflict of interest statement

RV has received financial compensation as a consultant or advisory board member from Canopy Growth Corporation, MyMD Pharmaceuticals, and Syqe Medical Ltd. MB-M is an employee of Canopy Growth Corporation and past board of directors member for AusCann Group Holdings Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1

Figure 2

References

    1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. (2012) 21:169–84. 10.1002/mpr.1359 – DOI – PMC – PubMed
    1. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. . Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. (1999) 156:1000–6. 10.1176/ajp.156.7.1000 – DOI – PubMed
    1. Scholten WD, Batelaan NM, Van Balkom AJ, Wjh Penninx B, Smit JH, Van Oppen P. Recurrence of anxiety disorders and its predictors. J Affect Disord. (2013) 147:180–5. 10.1016/j.jad.2012.10.031 – DOI – PubMed
    1. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. (2005) 162:1171–8. 10.1176/appi.ajp.162.6.1171 – DOI – PubMed
    1. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. . Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. (2005) 162:1179–87. 10.1176/appi.ajp.162.6.1179 – DOI – PMC – PubMed

Leave a Reply